SETD1A and Alzheimer disease: Cao et al. [23] found that administration of the SET1/MLL inhibitor WRD5-0103 inhibited the increase in H3K4me3 levels and the down-regulation of glutamatergic synaptic receptor expression, and restored synaptic plasticity in the prefrontal cortex, thus alleviating cognitive deficits in P301S Tau mice and five familial AD mutations mice.